A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis

Trial Profile

A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Factor XIII (Primary)
  • Indications Systemic scleroderma
  • Focus Therapeutic Use
  • Acronyms Sclero XIII
  • Most Recent Events

    • 11 Feb 2016 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network.
    • 23 Oct 2015 As per NCT record planned end date is Sep 2018 and as per UKCRN record it is Jun 2018. Though it is country specific single centre trial, kept it as per NCT as later date.
    • 25 Aug 2015 New source identified and integrated (European Clinical Trials Database - EudraCT2014-001101-40).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top